Transcenta Holding (HKSE:06628) Days Sales Outstanding : 515.10 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding Days Sales Outstanding?

Transcenta Holding's average Accounts Receivable for the six months ended in Dec. 2023 was HK$54.84 Mil. Transcenta Holding's Revenue for the six months ended in Dec. 2023 was HK$19.43 Mil. Hence, Transcenta Holding's Days Sales Outstanding for the six months ended in Dec. 2023 was 515.10.

The historical rank and industry rank for Transcenta Holding's Days Sales Outstanding or its related term are showing as below:

HKSE:06628' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.96 Med: 76.45 Max: 305.04
Current: 305.04

During the past 5 years, Transcenta Holding's highest Days Sales Outstanding was 305.04. The lowest was 65.96. And the median was 76.45.

HKSE:06628's Days Sales Outstanding is ranked worse than
88.29% of 888 companies
in the Biotechnology industry
Industry Median: 72.545 vs HKSE:06628: 305.04

Transcenta Holding's Days Sales Outstanding increased from Dec. 2022 (42.40) to Dec. 2023 (515.10).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Transcenta Holding Days Sales Outstanding Historical Data

The historical data trend for Transcenta Holding's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding Days Sales Outstanding Chart

Transcenta Holding Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

154.81

76.45

66.82

65.96

294.99

Transcenta Holding Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial				153.93	24.12	42.40	209.11	515.10

Competitive Comparison of Transcenta Holding's Days Sales Outstanding

For the Biotechnology subindustry, Transcenta Holding's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transcenta Holding's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's Days Sales Outstanding falls into.

Transcenta Holding Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Transcenta Holding's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (37.982	+	57.222)	/	2 )	/	58.899	*	365
=	47.602					/	58.899	*	365
=	294.99

Transcenta Holding's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (52.465	+	57.222)	/	2 )	/	19.431	*	365 / 2
=	54.8435					/	19.431	*	365 / 2
=	515.10

Transcenta Holding (HKSE:06628) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Transcenta Holding Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Transcenta Holding (HKSE:06628) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123

Website

https://www.transcenta.com

Transcenta Holding Ltd is a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the "PRC") and the USA.

Executives

Qian Xueming	2101 Beneficial owner
Shi Xiaohong	2501 Other
Lav Corporate Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Gp Iii, L.p.	2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p.	2101 Beneficial owner
Shi Yi	2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a.	2301 Trustee
Success Link International L.p.	2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited	2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si	2501 Other

Transcenta Holding (HKSE:06628) Headlines

No Headlines